


Vgenomics & Meril Genomics collaborate to revolutionise precision medicine in India

22 April 2025 | News



Access to NIPT, TB and Rare Disease diagnostics to benefit thousands nationwide

Noida-based Vgenomics, a leading precision health company, and Meril Genomics, a trusted diagnostics and molecular biology provider, have announced a groundbreaking partnership aimed at providing complementary advanced genomic diagnostics to hospitals and research centers throughout India.

This strategic collaboration combines Vgenomics' expertise in bioinformatics, AI-driven research, and translational genomics with Meril Genomics' proven capabilities in diagnostics and molecular biology.

The partnership will significantly enhance precision medicine accessibility, marking a milestone in genomic healthcare in India. Initiatives under this partnership include Non-Invasive Prenatal Testing (NIPT), which addresses the growing risk of chromosomal abnormalities such as Down syndrome, especially among expectant mothers with advanced maternal age. NIPT will facilitate early detection, contributing to safer pregnancies and healthier newborn outcomes across India.

In addition, the collaboration introduces targeted Next-Generation Sequencing (tNGS) for Tuberculosis (TB), significantly impacting India's healthcare landscape, where roughly 26% of Global TB cases occur annually. By enabling rapid and precise detection, tNGS will facilitate timely treatment and effective management of the disease, reducing its burden nationwide.

Furthermore, the initiative includes Whole Exome Sequencing (WES) for diagnosing rare diseases, addressing the needs of approximately 70 million affected individuals in India. Integrating WES with advanced AI analytics will significantly accelerate diagnostic timelines, enhance personalized treatment approaches, and reduce the prolonged diagnostic journey often faced by rare disease patients.